Association of statin use with cognitive decline in elderly African Americans

Neurology

Volumn 69, Issue 19, 2007, Pages 1873-1880

  Szwast, S J ^a   Hendrie, H C ^a   Lane, K A ^a   Gao, S ^a   Taylor, S E ^a   Unverzagt, F ^a   Murrell, J ^a   Deeg, M ^a,b   Ogunniyi, A ^c   Farlow, M R ^a   Hall, K S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AFRICAN AMERICAN; AGED; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 35948977729     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000279333.77404.d7     Document Type: Article

References (44)

1. Heart Protection Study Collaborative, G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [see comment] [summary for patients in Curr Cardiol Rep 2002;4:486-487; PMID: 12379169]. Lancet 2002;360:7-22.
2. Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative, G. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions [see comment]. Lancet 2004;363:757-767.
3. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531-1538.
4. Green RC, McNagny SE, Jayakumar P, Cupples A, Benke K, Farrer LA. Statin use and the risk of Alzheimer's disease: The MIRAGE Study. Alzheimer's and Dementia 2006;2:96-103.
5. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol Ser A Biol Sci Med Sci 2002;57:M414-418.
6. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia [erratum in 2001; 357:562]. Lancet 2000;356:1627-1631.
7. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-227.
8. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors [see comment]. Arch Neurol 2000;57:1439-1443.
9. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
10. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly. The Cardiovascular Health Study. Neurology 2005;65:1388-1394.
11. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-757.
12. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study [see comment]. Neurology 2004;63:1624-1628.
13. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047-1051.
14. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-224.
15. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
16. Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000;54:240-242.
17. Hall K, Murrell J, Ogunniyi A, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 2006;66:223-227.
18. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of Neurology 2003;60:510-515.
19. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-350.
20. Hognestad A, Aukrust P, Wergeland R, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clinical Cardiology 2004;27:199-203.
21. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005;20:133-136.
22. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. [see comment]. JAMA 2001;286:64-70.
23. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators [see comment]. Circulation 1999;100:230-235.
24. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events [see comment]. N Engl J Med 2002;347:1557-1565.
25. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97:33A-41A.
26. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease [see comment]. N Engl J Med 2005;352:29-38.
27. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy [see comment]. N Engl J Med 2005;352:20-28.
28. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004;61:668-672.
29. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174.
30. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76-80.
31. Expert Panel on Detection EaToHBCiA. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) [see comment]. JAMA 2001;285:2486-2497.
32. Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. [see comment]. Am J Psychiatry 1995;152:1485-1492.
33. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana [see comment]. JAMA 2001;285:739-747.
34. Hall KS, Ogunniyi AO, Hendrie HC, et al. A crosscultural community based study of dementias: methods and performance of the survey instrument, Indianapolis, USA, and Ibadan, Nigeria. Int J Methods Psychiatr Res 1996;6:129-142.
35. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC. Community screening interview for dementia (CSI 'D'); performance in five disparate study sites. Int J Geriatr Psychiatry 2000;15:521-531.
36. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
37. Hendrie HC, Albert MS, Butters MA, et al. The NIH Cognitive and Emotional Health Project: report of Critical Evaluation Study Committee. Alzheimer Dementia 2006;2:12-32.
38. Hendrie HC, Hall KS, Brittain HM, et al. The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. J Am Geriatr Soc 1988;36:402-408.
39. Unverzagt FW, Hall KS, Torke AM, et al. Effects of age, education, and gender on CERAD neuropsychological test performance in an African American sample. Clin Neuropsychol 1996;10:180-190.
40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
41. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880.
42. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006;40:1880-1883.
43. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-769.
44. Evans DA, Bienias JL. Alcohol consumption and cognition [comment]. N Engl J Med 2005;352:289-290.